Abstract
White matter hyperintensities (WMH) of presumed vascular origin are an MRI-based biomarker of cerebral small vessel disease (CSVD). WMH are associated with accelerated cognitive decline and increased risk of stroke and dementia, and are commonly observed in aging, vascular cognitive impairment, Alzheimer’s and Parkinson’s disease, and related dementias. The accurate, reliable, and rapid measurement of WMH in large-scale multi-site clinical studies with heterogeneous patient populations remains challenging. The diversity of MRI protocols and image characteristics across different studies as well as the diverse nature of WMH, in terms of their highly variable shape, size, distribution, and underlying pathology, adds additional complexity to this task. Here, we present segcsvdWMH, a novel convolutional neural network-based tool for quantifying WMH. segcsvdWMH is specifically designed for accurate and robust performance when applied to diverse clinical patient datasets. Central to the development of this tool is the curation of a large patient dataset (>700 scans) sourced from seven multi-site studies, encompassing a wide range of clinical populations, WMH burden, and imaging parameters. The performance of segcsvdWMH is evaluated against three widely used WMH segmentation tools, where we demonstrate significantly enhanced accuracy and robustness across a range of challenging conditions and datasets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Canadian Institute of Health Research (CIHR) grants PJT173387 and PJT190220.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Sunnybrook Research Institute gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-Senior Authors.
Competing interest: The authors declare that there are no conflicts of interest related to this manuscript, its preparation, or the research presented herein.
Formatting revision and minor clarifications added to text
Data Availability
This study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, which is publicly available upon application and approval at adni.loni.usc.edu. Additionally, it incorporated non-public datasets restricted by privacy agreements. Access to these datasets can be requested from the corresponding author under appropriate conditions.
